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 Response to Increases in Cigarette Prices
by Race/Ethnicity, Income, and Age Groups — United States, 1976–1993
Cigarette Prices — ContinuedTob cco use, particularly cigarette smoking, remains the leading cause of prevent-
able illness and death in the United States (1 ). Studies have shown that increases in
the price of cigarettes will decrease the prevalence of smoking and the number of
cigarettes smoked both by youth and adults (1,2 ). However, the potential impact of
price increases on minority and lower-income populations is an important considera-
tion (3,4 ). This report summarizes the analysis of data for 14 years from the National
Health Interview Survey (NHIS), which indicates that lower-income, minority, and
younger populations would be more likely to reduce or quit smoking in response to a
price increase in cigarettes.
Data from the NHIS from 1976 to 1980, 1983, 1985, and 1987 to 1993 were pooled
to conduct the analysis. The NHIS was administered to a nationally representative
multistage probability sample of the noninstitutionalized civilian population aged
≥18 years. Smoking histories were obtained for these years in supplements to the
NHIS; the overall response rate for these supplements was approximately 80%. Before
1992, participants were asked, “Have you smoked at least 100 cigarettes in your entire
life?” and “Do you smoke cigarettes now?” In 1992 and 1993, participants were asked,
“Do you now smoke cigarettes every day, some days, or not at all?” Current smokers
were persons who reported having smoked ≥100 cigarettes during their lifetimes and
who currently smoked cigarettes. Current smokers were asked, “On average, how
many cigarettes do you smoke per day?” Information on race/ethnicity, income, age,
and other demographic factors were obtained from the core of the NHIS question-
naire. Using data reported by the Tobacco Institute (5 ), the average price of a pack of
cigarettes for each state, adjusted for inflation, was merged into the NHIS data by year
and state of residence. The 14 cross-sections of the NHIS have 367,106 respondents;
of these, 355,246 respondents had complete demographic and price data (approxi-
mately 24,000 respondents per year).
Two types of multiple regression models were estimated. A probit (limited depend-
ent variable) model was used with the full sample (n=355,246) to estimate the change
in the probability of smoking (one for current smokers and zero for all other respon-
dents) for a change in the inflation-adjusted price (1982–1984 dollars). An ordinary
least squares model, restricted to current smokers (n=112,657) with self-reported
number of cigarettes smoked per day as the dependent variable, was used to estimate
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the relation between inflation-adjusted price and quantity of cigarettes consumed.
Both models controlled for year, region of the country (Northeast, South, Midwest,
and West)*, age, sex, race/ethnicity, education, marital status, family income, and ur-
banicity (based on residence in a metropolitan statistical area [MSA] central city, MSA
city, or rural area). Separate subpopulation models were estimated by race/ethnicity
(Hispanics, non-Hispanic blacks, and non-Hispanic whites), by age group (aged 18–24,
25–39, and ≥40 years), and by income group. Self-reported family incomes from all
survey years were inflation-adjusted to 1982–1984 dollars, and the sample median
was computed for all respondents reporting family income data. Respondents with
incomes equal to or below the median were compared with those above the median
income ($33,106 in 1997 dollars). All subpopulation models included the control vari-
ables used in the full models.
For all models, the effect of price is expressed as price elasticities. Price elasticity is
a standardized measure indicating the percentage change in the dependent variable
(i.e., smoking prevalence or number of cigarettes consumed per day) for a 1% change
in the inflation-adjusted price of cigarettes (independent variable) (6 ). Prevalence
price elasticity, using price coefficients from the probit regression models, is the per-
centage reduction in the prevalence of smoking that would be predicted from a 1%
price increase. Consumption price elasticity, using price coefficients from the linear
regression models, is the percentage reduction in the average number of cigarettes
smoked by persons who continue to smoke after a 1% price increase. Total price elas-
ticity is the sum of smoking prevalence and cigarette consumption price elasticities.
For all respondents, the models estimated a prevalence price elasticity of –0.15 and
a consumption price elasticity of –0.10, yielding a total price elasticity estimate of –0.25
(Table 1). Therefore, a 50% price increase could cause a 12.5% reduction in the total
U.S. cigarette consumption (i.e., 50% X –0.25=–12.5%), or approximately 60 billion
fewer cigarettes smoked per year. In the age-specific model, younger smokers were
more likely than older smokers to quit smoking, and after controlling for income, edu-
cation, and other nonprice variables, Hispanic smokers and non-Hispanic black smok-
ers were more likely than white smokers to reduce or quit smoking in response to a
price increase. This pattern was consistent for all age groups (Figure 1). Among both
non-Hispanic blacks and Hispanics, smokers aged 18–24 years were substantially
more price-responsive than smokers aged ≥40 years. Lower-income populations also
were more likely to reduce or quit smoking than those with higher incomes. The total
price elasticity was –0.29 for lower-income persons compared with –0.17 for higher-
income persons.
Reported by: MC Farrelly, PhD, JW Bray, MA, Research Triangle Institute, Research Triangle
Park, North Carolina. Office on Smoking and Health, National Center for Chronic Disease Pre-
vention and Health Promotion, CDC.
*Northeast=Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Penn-
sylvania, Rhode Island, and Vermont; Midwest=Illinois, Indiana, Iowa, Kansas, Michigan, Min-
nesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin;
South=Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisi-
ana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas,
Virginia, and West Virginia; and West=Alaska, Arizona, California, Colorado, Hawaii, Idaho,
Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. Models including
state-specific controls yielded results similar to those obtained with controls for region of the
country. Because sample sizes in subpopulation analyses were smaller, region of the country
rather than state-specific controls were used in all models.
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TABLE 1. Prevalence, consumption, and total price elasticities* using a probit regression model and least squares model to
estimate response to increases in cigarette prices†, by selected characteristics — United States, 1976–1993
Characteristic
Probit model Least squares model
Total
elasticity††No.
%
Smokers Coefficient (95% CI§)
Prevalence
elasticity¶ No.
Mean no.
cigarettes Coefficient (95% CI)
Consumption
elasticity**
Race/Ethnicity§§
White, non-Hispanic 281,482 29.4 –0.04 ±0.06 –0.05  90,829 21.49 –1.90 ±1.0 –0.09 –0.14
Black, non-Hispanic  43,141 32.8 –0.31 ±0.15 –0.36  14,158 14.12  0.50 ±1.9  0.04 –0.32
Hispanic  21,926 24.5 –0.76 ±0.26 –1.31   5,736 14.00 –7.50 ±4.1 –0.58 –1.89
Age group (yrs)
18–24  46,884 29.6 –0.29 ±0.15 –0.37  13,875 16.03 –3.34 ±1.9 –0.21 –0.58
25–39 119,510 34.2 –0.22 ±0.09 –0.25  42,177 19.49 –3.15 ±1.2 –0.17 –0.42
  ≥40 188,521 26.2 –0.04 ±0.07 –0.06  56,515 21.28 –0.73 ±1.2 –0.04 –0.10
Family income¶¶
≤Median income 154,602 31.7 –0.16 ±0.08 –0.20  51,780 19.24 –1.65 ±1.1 –0.09 –0.29
>Median income 156,940 27.5 –0.03 ±0.08 –0.05  48,422 20.82 –2.50 ±1.3 –0.12 –0.17
Income not reported  43,704 26.1 –0.15 ±0.14 –0.23  12,365 19.64 –0.60 ±2.3 –0.02 –0.25
Sex
Male 151,711 32.4 –0.18 ±0.08 –0.18  54,417 22.17 –1.91 ±1.2 –0.08 –0.26
Female 203,535 26.8 –0.07 ±0.07 –0.09  58,150 17.89 –1.87 ±1.0 –0.10 –0.19
Total 355,246 29.3 –0.12 ±0.05 –0.15 112,657 19.96 –1.94 ±0.8 –0.10 –0.25
 *Price elasticity is a ratio of the marginal change (i.e., per unit changes) between two variables and the average change between the same variables (7 ).
This ratio is a standardized measure that indicates the percentage change in the dependent variable (i.e., smoking prevalence or number of cigarettes
consumed per day) for a 1% change in the Consumer Price Index (CPI) adjusted price of cigarettes (independent variable).
†Cigarette prices were denominated in constant 1982–1984 dollars for all price elasticity estimates.
§Confidence interval.
¶Percentage reduction in prevalence of smoking for each 1% increase in the CPI adjusted price of cigarettes. The numerator (the marginal change) consists
of the regression coefficient for price multiplied by the average probability (based on the regression coefficient for price and variance terms) that a
person is a smoker. The denominator (the average change) is the ratio of the average number of surveyed persons who smoke (smoking prevalence)
to the average sample price.
**Percentage reduction in the number of cigarettes smoked per day for each 1% increase in the CPI adjusted price of cigarettes. The numerator is the
coefficient on price and the denominator is the ratio of the average number of cigarettes consumed per day to the average sample price.
††Calculated by summing the smoking prevalence and cigarette consumption price elasticities.
§§Data for racial/ethnic groups other than non-Hispanic whites, non-Hispanic blacks, and Hispanics were too small for meaningful analysis.
¶¶Family income data were denominated in constant 1982–1984 dollars for all price elasticity estimates.
Editorial Note: The findings in this report indicate that lower-income and minority
smokers would be more likely than other smokers to be encouraged to quit in
response to a price increase and thus would obtain health benefits attributable to quit-
ting. Other studies also have found that youth, young adults, and lower-income popu-
lations are the most price responsive (1,2,7 ). In this study, smokers with family
incomes equal to or below the study sample median were more likely to respond to
price increases by quitting than smokers with family incomes above the median (e.g.,
10% quitting compared with 3% quitting in response to a 50% price increase). After
controlling for income and education, Hispanics and non-Hispanic blacks are substan-
tially more price responsive than other smokers. Data from this model suggest that
Hispanic smokers were the most price responsive. Non-Hispanic black smokers would
respond to price increases primarily by quitting rather than reducing the number of
cigarettes smoked per day.
This study is subject to at least five potential limitations. First, because the analysis
is based on pooled cross-sectional surveys, the estimates of price elasticity could
underestimate the long-term response to price changes that would be observed from
longitudinal surveys. Second, this analysis does not control fully for other factors
unrelated to price (e.g., differences between states in social and policy environments)
that could reduce demand and be confounded with the state’s excise tax level. Third,
because not all respondents for whom price data was available reported family
income, the analysis by income categories could be less representative than other
subpopulation analyses. Fourth, the sample sizes in subpopulation analyses by race
and age (Figure 1) are reduced and make the estimation of price elasticities within
Hispanic Non-Hispanic Black Non-Hispanic White
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*Data for racial/ethnic groups other than non-Hispanic whites, non-Hispanic blacks, and His-
panics were too small for meaningful analysis.
FIGURE 1. Percentage decline in smoking in response to a 10% price increase on
cigarettes, by age and racial/ethnic group* — United States, 1976–1993
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Cigarette Prices — Continued
specific age groups by race less stable. Nevertheless, the pattern and magnitude of
the estimated parameters are consistent with those observed in previous studies, and
parameters for the control variables remained stable across models. Finally, because
of the changing composition (e.g., Mexican, Cuban, or Puerto Rican) and smaller size
of the Hispanic samples within the 14 NHIS samples used in this analysis, the esti-
mates for Hispanics are subject to greater error than those for non-Hispanic blacks
and non-Hispanic whites.
Comprehensive measures for promoting cessation and reducing the prevalence of
smoking include increasing tobacco excise taxes, enforcing minors’ access laws, re-
stricting smoking in public places, restricting tobacco advertising and promotion, and
conducting counter-advertising campaigns. Because state tax increases are more ef-
fective when combined with a comprehensive tobacco prevention and control pro-
gram (8 ), price increases should be combined with such programs to increase their
public health impact. Court settlements with several states and other market factors
have resulted in the tobacco industry increasing the wholesale price of cigarettes by
12.2% since January 1997 (9 ). Although this and potential future industry price in-
creases will reduce smoking prevalence and consumption—particularly among ado-
lescents and young adults (1 )—most adult smokers will continue to smoke and pay
the higher cigarette prices. Tobacco-use prevention and cessation programs should be
made available to benefit those populations paying the greatest share of the increased
prices. Smoking prevention will always remain a primary public health objective, but
public health efforts encouraging cessation particularly are needed for smokers aged
≥40 years, who would be the most likely group to continue smoking and paying the
higher cigarette prices. In addition, tobacco-use prevention and cessation programs
should be directed toward lower-income and minority populations in which the bur-
den of tobacco-related disease is high (10 ).
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Clinical Sepsis and Death in a Newborn Nursery
Associated with Contaminated Parenteral Medications — Brazil, 1996
Contaminated Parenteral Medications — ContinuedIn October 1996, a to al of 35 newb rn infants died in a 26-bed nursery of a 200-bed
hospital in Roraima, Brazil; these deaths represented a significant increase over the
baseline mortality rate in the nursery (6.0 versus 1.7 per 100 live births; p<0.01).
Twenty of the deaths were attributed to sepsis. Fatal episodes of sepsis began 24–
72 hours after birth. Although an investigation by the Roraima Health Department re-
sulted in an improvement of infection control, increased episodes of fever and clinical
sepsis persisted. As a result, in November 1996, the Secretary of Health of Roraima,
Brazil Ministry of Health, requested that CDC assist in the investigation. This report
summarizes this investigation, which implicated locally produced intravenous (IV)
solutions as the source of the outbreak and underscores the need to assure proper
quality control of parenteral medications and the importance of nosocomial infection
surveillance.
In November 1996, CDC conducted a cohort study to identify risk factors for the
development of fever. A case was defined as fever of 100.4 F (38 C) without a recog-
nized cause in any neonate who was admitted to the hospital nursery on October 1, 5,
15, or 25 (these dates were chosen to represent the entire month) and who received
antimicrobial therapy for sepsis. Six of the 66 patients admitted to the nursery on
these days met the case definition. When case- and non-case-patients were com-
pared, neither sex, gestational age, birthweight, nor Apgar score at 5 minutes were
associated with the development of fever. In comparison, Apgar scores at 1 minute of
<8 (five of 23 versus one of 43; p=0.01) and insertion of a peripheral IV catheter with
receipt of parenteral medications (six of nine versus zero of 57; p<0.01; relative risk
[RR]=20) were associated with the development of fever. Because this cohort study
strongly implicated the insertion of peripheral IVs and receipt of parenteral medica-
tions as risk factors for the development of fever, a second cohort study was con-
ducted to determine whether IVs were associated with the development of fever
before the time of the outbreak. This second cohort included all patients admitted to
the hospital nursery on June 1, 5, 15, or 25, dates preceding the time of the increase in
death rate. None of the 55 patients admitted to the nursery during the June dates
developed fever, including 11 patients who had been exposed to parenteral medica-
tions. The attack rate for fever following exposure to parenteral medications was sig-
nificantly higher on the four dates in October compared with the four dates in June
(six of nine versus zero of 11; p<0.01; RR=undefined). 
To identify risk factors for death attributed to clinical sepsis, CDC conducted a case-
control study on infants admitted to the nursery during October 1996. The case defini-
tion was expanded to include death following the onset of fever and clinical sepsis.
Twenty infants admitted to the nursery during October met the case definition;
40 birthdate-matched patients were included as controls. Case-patients were more
likely than controls to have a lower birthweight (mean: 2.3 kg versus 3.3 kg; p=0.01),
lower Apgar score at 1 minute (mean: 6.5 versus 7.7; p=0.01) or 5 minutes (mean:
8.0 versus 8.8; p=0.01), lower gestational age (mean: 33.8 versus 38.8 weeks; p=0.01),
or a peripheral IV and to have received parenteral medications (20 of 20 versus zero
of 40; p=0.01). Various parenteral medications (i.e., glucose, aminophylline, calcium
gluconate, penicillin, sodium chloride, potassium, and sodium bicarbonate) were
610 MMWR July 31, 1998
administered to case-patients; only glucose, aminophylline, and bidistilled water
(used to reconstitute medications) were administered to all case-patients. All case-
patients developed fever only after they were exposed to the parenteral medications.
Thirteen of 14 blood cultures taken from case-patients ≤2 days after the onset of fever
were negative for bacterial growth; one blood culture was positive for Klebsiella pneu-
moniae. 
Samples of parenteral fluids and medications used in the nursery were examined
for bacterial and/or endotoxin contamination. Endotoxin was measured using the
limulus  amoebocyte assay. All cultures of these solutions were negative for bacterial
growth. However, six of 13 unopened vials of bidistilled water for injection and 12 of
15 unopened vials of 25% glucose, manufactured by Hipolabor Farmaceutica Ltda.
(Sabara, Minas Gerais, Brazil), had elevated endotoxin levels of 0.8–5.8 endotoxin
units (EU)/mL (mean: 3.8 EU/mL) and 0.8–1.9 EU/mL (mean: 1.2 EU/mL), respectively.
The United States Pharmacopeia (U.S.P.) endotoxin limit on water for injection is
0.25 EU/mL and for glucose (5%–70%) is 0.5 EU/mL. Caked amorphous-like material
and bacterial cells were observed by scanning electron microscopy in samples of
bidistilled water containing elevated levels of endotoxin.
Reported by: A Wanderley, Roraima Health Dept; C Wanderley, Hospital e Maternidade Nossa
Senhora de Nazare, Boa Vista, Roraima; Ministry of Health, Brazil. Hospital Infections Program,
National Centers for Infectious Diseases; and EIS officers, CDC.
Editorial Note: The findings in the investigation described in this report implicated
insertion of a peripheral IV line and receipt of parenteral medications as resulting in
clinical sepsis and death during the outbreak. Laboratory results documented endo-
toxin contamination of unopened vials of parenteral medications administered to in-
fants, suggesting intrinsic contamination of these products.
The release of endotoxin into the circulatory system is the initiating event of sepsis
associated with gram-negative organisms. Subsequently, reactions may range from
no detectable response to the onset of profound shock and death (1,2 ). Such reac-
tions are highly dependent on the body mass of the patient (3 ). Because the minimal
pyrogenic dose of endotoxin is 5 EU/kg (4 ), 2–3 mL of the contaminated bidistilled
water (mean level of contamination: 3.8 EU/mL) would have been sufficient to evoke a
pyrogenic reaction in an average 4 lbs, 8 oz (2000 g) infant. As a result, IV administra-
tion of these endotoxin-contaminated fluids (bidistilled water and/or 25% glucose)
explained the increased number of febrile reactions detected during this outbreak. All
infants receiving parenteral medications were receiving bidistilled water and glucose.
Attack rates of 70% among these infants suggest that not all lots of bidistilled water
and glucose were contaminated.
Exposure of the infants to parenteral fluids contaminated with endotoxin also may
have been sufficient to cause the increased number of deaths during October.
Previous studies on both humans and animals have demonstrated that endotoxin is
capable of inducing clinical sepsis and death (5 ). Infants with low birthweight and
gestational age were probably at increased risk for death because of the smaller
amount of endotoxin required to cause serious pyrogenic reactions.
An investigation at the hospital described in this report previously had detected
several breakdowns in aseptic technique and infection-control practices. Blood cul-
tures collected and processed during October (mean: 8 days after the onset of fever)
revealed the presence of bloodstream infection (BSI) in several infants. Exposure to
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endotoxins may have resulted in higher BSI rates by prolonging the exposure of
infants to peripherally inserted IVs and breaks in aseptic technique during their
manipulation. Despite a continued increase in episodes of unexplained fever, BSIs and
deaths decreased in November after an improvement in infection-control practices.
Unopened vials of contaminated medication were undamaged and had no evi-
dence of tampering, suggesting that contamination most likely occurred during the
manufacturing process. Without appropriate manufacturing processes, endotoxin can
contaminate solutions and reagents (6 ). Many gram-negative organisms, which can
release endotoxin, require few nutrients and can grow in distilled water at 39.2 F (4 C).
In addition, endotoxins can survive exposure to steam autoclaving, organic solvents,
acids, ethanol, and sterilizing liquids. Only dry heat (≥482 F [≥250 C] for 30 minutes or
≥356 F [≥180 C] for 3 hours) can assure the elimination of endotoxin (7 ). 
The manufacturing plant in Minas Gerais, Brazil, where the medications implicated
in this outbreak were made, was closed when inadequate quality-control testing was
observed by the Secretary of Health of Minas Gerais. Although all Brazilian state sec-
retaries of health were notified of the closure, no nationally coordinated product recall
was performed. Based in part on the findings of this investigation, the Secretary of
Health of Minas Gerais decided not to allow reopening of the manufacturing facility
until quality-control measures were improved. 
The routine surveillance of nosocomial infections at the hospital level is essential
for the early detection and control of such epidemics. Clusters of pyrogenic reactions
should always lead to an evaluation of possible product contamination. Surveillance
also is important at a nationwide level. In this outbreak, contaminated medications
were distributed widely throughout Brazil, and similar episodes of sepsis among neo-
nates were reported from other nurseries around the country. 
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Use of Clinical Preventive Services by Adults Aged <65 Years
Enrolled in Health-Maintenance Organizations — United States, 1996
Clinical Preventive Services — ContinuedHealth-maintenance organizations (HMOs) are accountable for the preventive care
of approximately one quarter of the U.S. population (1 ), and public health agencies
have an increasing role in assessing the quality of care for populations enrolled in
HMOs (2–4 ). The Health Plan Employer Data and Information Set (HEDIS 3.0) (5 ) re-
ports on the performance of HMOs and is sponsored and maintained by the not-for-
profit National Committee for Quality Assurance (NCQA).* This report summarizes
state-specific HEDIS estimates for the delivery of four clinical preventive services:
screening mammography and Papanicolaou (Pap) tests for women, screening retinal
examinations for persons with diabetes, and advising smokers to quit. The advice-to-
quit-smoking data from 12 states represented by HEDIS is then compared with data on
insured respondents from the corresponding 12 states surveyed by the Behavioral
Risk Factor Surveillance System (BRFSS).† These findings underscore the potential
public health importance of HEDIS data (e.g., creating the capacity to assess statewide
prevention interventions) and highlights some of the methodologic issues of compar-
ing performance measures from HEDIS to the BRFSS.
The HEDIS data used in this report are for commercial HMO enrollees only (i.e.,
persons who joined the HMO through an employer group policy or an individual or
family policy [excluding Medicaid and Medicare beneficiaries]). The 1996 HEDIS data
used in this analysis were reported by 320 HMOs in 42 states and the District of
Columbia; these HMOs are comparable to the 660 HMOs nationwide by HMO type,
regional location, and tax status (5 ). Data for the measures on mammography, Pap
tests, and retinal examinations for persons with diabetes were obtained from admin-
istrative data with optional medical record supplementation using standard HEDIS 3.0
methodology (5 ).§ To obtain data about the advice-to-quit-smoking measure, NCQA
required HMOs to use independent contractors to administer and analyze a stand-
ardized mailed survey.¶ The median response rate was 41%. A “national” HEDIS
prevalence rate for each measure was calculated by first adjusting for HMO plan size
and then for state population size.
The BRFSS is an ongoing, state-based, random-digit–dialed telephone survey of
noninstitutionalized persons aged ≥18 years in the 50 states and the District of Colum-
bia. All persons responding to the BRFSS questionnaire were asked 1) whether they
had health insurance, 2) what specific preventive health services they had received,
and 3) the duration since they had received the service(s). BRFSS respondents report-
ing Medicare or Medicaid coverage or no insurance at all were excluded from the
analysis. In 1996, a total of 12 states used the optional BRFSS module that contained
*The source for data contained in this article is Quality Compass  and is used with the
permission of the NCQA.
†The estimates for mammography, Pap tests, and retinal examination rates from HEDIS were
not compared with BRFSS because of the differences between records-based and self-reported
measurement systems.
§The HEDIS data on advice to smokers, Pap tests, and retinal examinations were derived from
members who were enrolled continuously in an HMO for at least 1 year. Calculation of HEDIS
mammography coverage rates required at least 2 years of continuous enrollment. HEDIS does
not permit more than one 45-day break in enrollment during the reporting year.
¶Within each HMO, the survey was mailed to 1860 randomly chosen commercial enrollees aged
≥18 years. Response rate was calculated as the number of completed surveys divided by the
number of persons in the sample minus (the number of ineligible persons surveyed plus the
number of persons who could not be contacted).
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the advice-to-quit-smoking question. Estimates were weighted to the states’ age, sex,
and race distribution of adults. Statistical Analysis System (SAS) software (6 ) was
used to calculate point estimates, and SUDAAN (7 ) software was used to calculate
95% confidence intervals. The response rate for the BRFSS was estimated by the
CASRO method as 63.8% (8 ). Standardization of HEDIS and BRFSS data to the same
population was not possible because HEDIS provided only aggregated data.
Among women aged 52–64 years, a median of 71.9% (range: 61.9%–83.2%) of
HEDIS HMO records showed receipt of a mammogram during the preceding 2 years
(Table 1). The prevalence of mammography was highest in New England states and
lowest in the east south central states (Table 2). Among women aged 21–64 years, a
median of 72.7% (range: 51.5%–85.6%) of HMO records showed receipt of a Pap test
during the preceding 3 years. The prevalences of Pap test receipt for the HEDIS popu-
lation were highest in the New England states and lowest in the east south central
states. Among persons with diabetes aged 31–64 years in the HEDIS population, a
median of 39.5% (range 19.2%–67.7%) had had a retinal examination during the pre-
vious year. Among smokers aged 18–64 years who were examined by a health-care
provider during the previous year, a median of 63.0% (range: 32.3%–71.8%) reported
receiving advice to quit.
HEDIS data were compared with BRFSS data for the advice-to-quit measure for
12 states and the District of Columbia. Among HEDIS smokers aged 18–64 years who
had been examined by a health-care provider during the previous year, a median of
63.2% (range: 56.2%–71.8%) reported receiving advice to quit; in comparison, among
the insured BRFSS smokers who had been examined by a physician for a routine
check-up during the previous year, a median of 62.4% (range: 49.9%–70.8%) reported
receiving advice to quit (Table 3).
Reported by: F Ahmed, J Thompson, National Committee for Quality Assurance, Washington,
DC. The following BRFSS coordinators: B Bender, Arizona; J Senner, PhD, Arkansas; M Leff,
MSPH, Colorado; F Breukelman, Delaware; C Mitchell, District of Columbia; M Perry, Kansas;
K Asher, Kentucky; R Meriwether, MD, Louisiana; D Maines, Maine; P Arbuthnot, Mississippi;
T Murayi, PhD, Missouri; T Melnik, DrPH, New York; K Passaro, PhD, North Carolina; N Hann,
MPH, Oklahoma; L Redman, Virginia; F King, West Virginia. Div of Adult and Community Health,
National Center for Chronic Disease Prevention and Health Promotion; Office of Program Plan-
ning and Evaluation; Div of Prevention Research and Analytic Methods, Epidemiology Program
Office; and an EIS Officer, CDC.
Editorial Note: The findings in this report indicate that the prevalences of preventive-
care practices of HMOs in the United States varied among the states and regions.
HEDIS data represent a large-scale private-sector effort to provide data that could
have valuable public health applications. HEDIS measures are potentially useful for
public-sector assessment of the quality of care provided by HMOs, especially because
HMOs are increasingly contracted by the states and the Health Care Financing Admini-
stration to care for Medicaid and Medicare populations. This report provides the first
published state-specific estimates of HEDIS performance and comparison of private-
sector HEDIS data to the BRFSS, a public-sector data set. 
The findings in this report are subject to at least four limitations. First, it is unclear
whether HEDIS is representative of a state’s HMO population because the penetration
of HMOs in each state’s health-care system varies widely (1 ). Because there is no
government or purchaser mandate to report data to HEDIS, HMOs can voluntarily
choose to submit HEDIS performance data (5 ). HEDIS data for 1996 were not audited
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TABLE 1. Estimated prevalence of use of selected clinical preventive services by adults aged <65 years enrolled in
health-maintenance organizations (HMOs), by service and state — United States, Health Plan Employer Data and Information
Set (HEDIS), 1996 — Continued
State
Mammography*
Papanicolaou
smear†
Retinal examinations for
persons with diabetes§
Receipt of advice
to quit smoking¶
No. HMOs
reporting** % (95% CI††)
No. HMOs
reporting % (95% CI)
No. HMOs
reporting % (95% CI)
No. HMOs
reporting % (95% CI)
Arkansas  2 71.7 (±5.0)  2 69.6 (± 4.8)  2 23.2 (± 6.0)  NA§§
Arizona  8 75.1 (±1.3)  8 80.8 (± 2.8)  7 40.7 (± 2.8)  5 63.7 (± 3.3)
California  6 74.7 (±3.5)  6 73.1 (± 4.5)  6 51.6 (± 9.5)  6 61.4 (± 6.3)
Colorado  8 74.2 (±3.2)  8 73.8 (± 2.9)  8 46.9 (± 6.7)  6 61.9 (± 8.2)
Connecticut**  7 69.7 (±3.9)  7 70.7 (± 4.3)  7 42.5 (± 5.0)  6 61.7 (± 9.7)
Delaware**  7 70.3 (±0.5)  6 71.2 (± 0.2)  7 37.7 (± 0.7)  3 61.9 (± 4.7)
District of
Columbia**  3 76.5 (±0.4)  3 82.9 (± 0.1)  3 56.5 (± 0.6)  4 66.5 (± 3.3)
Florida 30 70.8 (±0.8) 23 67.4 (± 3.0) 26 37.9 (± 2.9)  8 64.4 (± 3.2)
Georgia  4 69.2 (±6.3)  6 65.5 (± 7.1)  6 30.5 (± 5.0)  2 61.1 (±21.9)
Hawaii  1 77.7 (±0.3)  1 76.3 (± 0.2)  1 67.7 (± 0.5)  1 65.9 (± 3.2)
Illinois**  7 66.6 (±4.9)  8 67.9 (± 6.6)  7 29.1 (± 7.8)  5 64.0 (± 5.1)
Indiana**  5 75.6 (±6.0)  6 76.4 (± 8.8)  5 39.1 (± 9.7)  4 64.2 (± 6.0)
Iowa  1 78.2 (±3.3)  1 72.7 (± 0.5)  1 47.0 (± 3.9)  1 54.8 (± 6.2)
Kansas  6 72.0 (±3.2)  6 71.3 (± 5.4)  5 48.0 (±14.4)  3 63.2 (±11.5)
Kentucky  3 64.3 (±2.5)  3 69.3 (± 5.2)  3 43.3 (± 4.5) NA
Louisiana  4 66.6 (±3.0)  4 51.5 (±17.0)  4 26.9 (± 6.2)  3 56.2 (± 5.1)
Maine  3 83.2 (±0.9)  3 83.7 (± 0.3)  3 56.0 (± 1.8)  3 71.8 (± 4.2)
Maryland** 15 68.3 (±0.3) 15 70.0 (± 0.1) 13 42.8 (± 2.2) 11 67.9 (± 2.4)
Massachusetts** 12 80.2 (±0.2) 10 82.0 (± 0.9) 10 56.7 (± 2.1) 10 71.1 (± 3.0)
Michigan 12 75.3 (±2.3) 12 76.8 (± 3.2) 12 39.5 (± 5.8) 10 67.9 (± 2.6)
Minnesota  2 77.9 (±9.2)  2 85.6 (± 1.8)  2 51.3 (±22.4)  2 65.6 (± 5.1)
Missouri**  9 69.4 (±4.7)  9 68.5 (± 3.2) 12 32.3 (± 4.7)  5 62.8 (± 2.7)
Nebraska  3 72.5 (±2.5)  3 76.6 (± 4.7)  3 19.2 (± 4.1)  3 62.5 (± 4.9)
Nevada  1 61.9 (±1.3)  1 69.3 (± 0.4) NA NA
New Hampshire  3 77.9 (±0.8)  3 81.5 (± 0.3)  3 60.9 (± 1.5)  2 69.6 (± 4.6)
New Jersey**  9 65.8 (±4.8)  8 64.4 (± 3.9)  9 36.3 (± 6.1)  5 53.9 (± 7.8)
New Mexico  5 67.9 (±3.6)  4 65.1 (± 7.7)  4 42.7 (± 6.6)  1 32.3 (± 2.2)
New York** 26 70.8 (±1.7) 27 74.2 (± 2.2) 27 50.2 (± 2.4) 14 62.1 (± 2.5)
North Carolina  6 70.8 (±5.2)  8 74.1 (± 3.4)  8 36.9 (± 5.3)  4 63.3 (± 2.9)
Ohio 16 70.6 (±2.9) 16 69.9 (± 2.8) 16 35.4 (± 4.7)  5 67.3 (± 5.2)
Oklahoma  6 74.1 (±2.5)  6 73.5 (± 1.6)  6 34.9 (± 4.9)  3 56.4 (± 3.2)
Oregon  7 74.2 (±1.0)  7 74.9 (± 1.9)  7 44.1 (± 2.9)  3 61.4 (±18.1)
Pennsylvania** 23 73.4 (±0.2) 21 72.7 (± 0.1) 23 35.4 (± 0.1) 10 66.5 (± 2.7)
South Carolina**  5 74.7 (±1.4)  5 66.3 (± 2.9)  5 25.7 (± 3.3)  3 58.5 (± 7.6)
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South Dakota NA  1 66.2 (± 2.2) NA NA
Tennessee  8 64.3 (± 3.3)  8 67.5 (± 2.5)  8 25.4 (± 6.2)  4 52.4 (± 6.2)
Texas 21 68.9 (± 2.5) 22 73.4 (± 2.4) 20 35.1 (± 2.6)  6 59.7 (± 4.6)
Utah  3 68.2 (± 4.4)  3 62.7 (± 2.5)  3 25.2 (± 4.3)  1 51.6 (± 3.6)
Vermont  1 81.0 (± 2.6)  1 84.4 (± 2.4)  1 59.4 (± 3.2) NA
Virginia**  5 63.5 (± 4.2)  7 66.9 (± 3.5)  5 27.7 (± 3.7)  5 64.6 (± 3.5)
Washington 10 76.4 (± 0.4) 10 77.5 (± 0.2) 10 56.6 (± 1.0)  7 60.8 (± 6.1)
West Virginia  1 69.2 (± 0.2)  1 71.4 (± 0.1)  1 32.4 (± 0.3)  1 69.1 (± 2.5)
Wisconsin**  6 75.2 (± 4.1)  6 78.1 (± 3.1)  6 59.7 (± 8.7)  4 64.5 (± 5.6)
 *Women aged 52–64 years who had documented receipt of the service during the 2 years preceding the inquiry.
†Women aged 21–64 years who had documented receipt of the service during the 3 years preceding the inquiry. Denominator may exclude women who
had had a hysterectomy.
§Adults aged 31–64 years who had diabetes diagnosed and who had documented receipt of a retinal examination during the previous year.
¶Adults aged 18–64 years who reported having seen a health-care provider during the year preceding the inquiry; data are from the HEDIS membership
satisfaction survey.
**HMOs for which the primary service area could not be determined had their preventive service coverage rates reported for each of the multiple states
served.
††Confidence interval.
§§Not available.
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TABLE 2. Estimated prevalence of use of selected clinical preventive services, by region and service — United States, Health
Plan Employer Data and Information Set (HEDIS), 1996
Region
Mammography*
Papanicolaou
smear†
Retinal examinations
for persons with diabetes§
Receipt of advice
to quit smoking¶
% (95% CI**) % (95% CI) % (95% CI) % (95% CI)
New England 77.5 (±1.3) 79.2 (±1.6) 53.4 (±2.3) 68.4 (±3.5)
Middle Atlantic 70.6 (±1.2) 71.7 (±1.3) 42.6 (±1.7) 61.8 (±2.2)
East North Central 71.8 (±2.0) 72.7 (±2.3) 37.9 (±3.5) 65.8 (±2.0)
West North Central 73.9 (±3.9) 74.7 (±3.2) 41.0 (±7.1) 62.2 (±2.8)
South Atlantic 70.0 (±0.8) 69.1 (±1.4) 34.8 (±1.7) 63.8 (±1.5)
East South Central 64.3 (±2.9) 68.3 (±2.6) 33.0 (±6.7) 52.4 (±6.5)
West South Central 69.4 (±1.8) 69.8 (±2.6) 32.8 (±2.2) 58.7 (±2.8)
Mountain 71.4 (±2.0) 72.7 (±3.3) 40.4 (±3.6) 56.5 (±5.7)
Pacific 74.9 (±2.0) 73.9 (±2.7) 52.1 (±4.4) 61.4 (±5.5)
National
††
71.6 (±0.7) 72.1 (±0.9) 40.8 (±1.0) 62.3 (±0.7)
 *Women aged 52–64 years with documented receipt of service during the preceding 2 years.
†Women aged 21–64 years with documented receipt of service during the preceding 3 years. Denominator may exclude women who had had a
hysterectomy.
§Adults aged 31–64 years who had diabetes diagnosed and who had documented receipt of a retinal examination during the preceding year.
¶Smokers aged 18–54 years who had seen a health-care provider during the previous year and reported receipt of service.
**Confidence interval.
††National rate adjusted for participating states’ population.
uniformly and may overrepresent HMOs in urban areas (5 ). Second, HEDIS and
BRFSS populations could not be standardized to the same population. A county-by-
county comparison of a large, multistate HMO population with the insured BRFSS
population showed that HMO enrollees represented fewer minorities and were
younger, were more likely to be married, and had higher income and education levels
(9 ). Third, although the advice-to-quit-smoking measure in both populations was
assessed by self-report, there were differences in both the mode of administration and
wording of questions. BRFSS advice-to-quit rates may be overestimated because dur-
ing routine checkups patients may be more likely to receive preventive advice than
during other outpatient encounters. Finally, the low response rate for HEDIS may
reflect nonresponse bias.
HEDIS is a potentially valuable means of tracking the use of clinical preventive ser-
vices for a large proportion of the U.S. population. Of the four measures studied, the
national health objective for 2000 has been met only for mammography for women
TABLE 3. Estimated prevalence of receipt of advice to quit smoking for adults aged
<65 years, by selected states — United States, Health Plan Employer Data and
Information Set (HEDIS) and Behavioral Risk Factor Surveillance System (BRFSS)*,
1996
State
Reported receipt of advice to quit smoking†
HEDIS BRFSS
% (95% CI§) % (95% CI)
Arizona 63.7 (± 3.3) 51.6 (± 9.8)
Colorado 61.9 (± 7.0) 68.1 (± 8.5)
Delaware¶ 61.9 (± 4.7) 66.2 (± 3.6)
District of Columbia¶ 66.5 (± 3.9) 62.4 (±11.4)
Kansas 63.2 (±11.5) 49.9 (± 8.4)
Louisiana 56.2 (± 5.1) 51.5 (± 9.1)
Maine 71.8 (± 4.2) 66.9 (± 9.4)
Missouri 62.8 (± 2.5) 59.5 (± 9.1)
New York¶ 62.1 (± 2.8) 69.5 (± 6.7)
North Carolina 63.3 (± 2.9) 64.5 (± 6.5)
Oklahoma 56.4 (± 3.2) 59.2 (± 8.7)
Virginia¶ 64.6 (± 4.2) 70.8 (± 6.8)
West Virginia¶ 69.1 (± 2.5) 62.0 (± 7.4)
Median 63.2 62.4
*Persons responding to the BRFSS questionnaire were asked, “Do you have any kind of
health-care coverage, including health insurance, prepaid plans such as health-maintenance
organizations (HMOs), or government plans such as Medicare?” Those responding “yes” were
asked, “What type of health-care coverage do you use to pay for most of your medical care?”
Those reporting Medicare, Medicaid, or no insurance coverage were excluded from this analy-
sis.
†Smokers aged 18–64 years who reported visiting a provider (HEDIS) or physician (BRFSS)
during the preceding year and received advice to quit. The BRFSS asked the advice-to-quit
smoking question in 12 states and the District of Columbia; the HEDIS data on this measure
is from the same 12 states and the District of Columbia.
§Confidence interval.
¶HMOs whose primary service area could not be determined had their preventive service
coverage rates reported for each of the multiple states served.
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aged 52–64 years. To track prevention interventions provided by various health-
delivery systems, more comparable population-based performance measures need to
be developed. Such measures would benefit both health departments and HMO man-
agers by identifying areas for improvement for clinical preventive service delivery (2–
4 ) and enable states to monitor the effectiveness of communitywide health programs.
References
1. Anonymous. The InterStudy competitive edge: HMO industry report 7.2 1997. St. Paul, Min-
nesota: InterStudy Publications, Decision Resources, Inc., 1997.
2. Harris JR, Caldwell B, Cahill K. Measuring the public’s health in an era of accountability: lessons
from HEDIS. Am J Prev Med 1998;14(suppl 3):9–13.
3. CDC. Prevention and managed care: opportunities for managed care organizations, purchasers
of health care, and public health agencies. MMWR 1995;44(no. RR-14).
4. Baker EL, Melton RJ, Stange PV, et al. Health reform and the health of the public: forging com-
munity health partnerships. JAMA 1994;272:1276–82.
5. Thompson JW, Bost J, Ahmed F, Ingalls CE, Sennett C. The NCQA’s Quality Compass: evalu-
ating managed care in the United States. Health Affairs 1998;17:152–8.
6. SAS Institute Inc. Statistical Analysis System/STAT user’s guide, version 6. 4th ed. Vol 1. Cary,
North Carolina: SAS Institute Inc., 1989:943.
7. Shah BV, Barnwell BG, Bieler GS. SUDAAN user’s manual, version 6.4. 2nd ed. Research Tri-
angle Park, North Carolina: Research Triangle Institute, 1996.
8. White AA. Response rate calculation in RDD telephone health surveys: current practices. In:
Proceedings of the American Statistical Association, Section of Survey Research Methods.
Washington, DC: American Statistical Association, 1983:277–82.
9. Cogswell ME, Nelson D, Koplan JP. Surveying managed care members on chronic disease.
Health Affairs 1997;16:219–27.
Clinical Preventive Services — Continued
Erratum: Vol. 47, No. RR-5
In the MMWR Recommendations and Reports, “Guidelines for the Use of An-
tiretroviral Agents in HIV-Infected Adults and Adolescents,” on page 43, information
was incorrectly presented in the summary section. The sentence beginning on the
10th line from the end of the summary should read, “In general, a protease inhibitor
and two nucleoside  reverse transcriptase inhibitors should be used initially.”
Errata: Vol. 47, No. 28
In the article “Outbreak of Acute Febrile Illness Among Athletes Participating in
Triathlons—Wisconsin and Illinois, 1998” on page 585, in the first sentence of the first
paragraph the date was incorrect. The sentence should begin, “On July 14, 1998, ...”.
In the article “Wild Poliovirus Transmission in Bordering Areas of Iran, Iraq, Syria,
and Turkey, 1997–June 1998,” on page 589 in Figure 1, cases with onset in 1997 were
omitted from provinces labeled A, F, I, and R. Following is the corrected figure.
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FIGURE 1. Location of provinces/governorates on borders of Iran, Iraq, Syria, and
Turkey and distribution of virologically confirmed poliomyelitis cases, January
1997–June 1998
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FIGURE I. Selected notifiable disease reports, comparison of provisional 4-week totals
ending July 25, 1998, with historical data — United States
Anthrax - Plague 4
Brucellosis 42 Poliomyelitis, paralytic 1
Cholera 6 Psittacosis 30
Congenital rubella syndrome 5 Rabies, human -
Cryptosporidiosis* 1,048 Rocky Mountain spotted fever (RMSF) 126
Diphtheria 3 Streptococcal disease, invasive Group A 1,377
Encephalitis: California* 3 Streptococcal toxic-shock syndrome* 37
eastern equine* - Syphilis, congenital** 131
St. Louis* - Tetanus 17
western equine* - Toxic-shock syndrome 71
Hansen Disease 65 Trichinosis 6
Hantavirus pulmonary syndrome*† 6 Typhoid fever 166
Hemolytic uremic syndrome, post-diarrheal* 25 Yellow fever -
HIV infection, pediatric*§ 127
Cum. 1998Cum. 1998
TABLE I. Summary — provisional cases of selected notifiable diseases,
United States, cumulative, week ending July 25, 1998 (29th Week)
 -: no reported cases
 *Not notifiable in all states.
 † Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).
 § Updated monthly to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and
TB Prevention (NCHSTP), last update June 28, 1998.
 ¶ Updated from reports to the Division of STD Prevention, NCHSTP.
DISEASE DECREASE INCREASE
CASES CURRENT
4 WEEKS
Ratio (Log Scale)*
AAAA
AAAA
AAAA
AA
AA
AA Beyond Historical Limits
420.250.1250.06250.03125
1,070
503
128
93
1
132
25
289
16
AAAA
AAAA
AAAA
AAAA
AAAA
AAAA
0.5 1
Hepatitis A
Hepatitis B
Hepatitis, C/Non-A, Non-B
Legionellosis
Measles, Total
Mumps
Pertussis
Rubella
Meningococcal Infections
*Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and
subsequent 4-week periods for the past 5 years). The point where the hatched area begins is
based on the mean and two standard deviations of these 4-week totals.
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TABLE II. Provisional cases of selected notifiable diseases, United States,
weeks ending July 25, 1998, and July 19, 1997 (29th Week)
UNITED STATES 23,929 32,521 291,740 252,518 1,156 592 169,556 157,755 2,149 1,908
NEW ENGLAND 830 1,454 11,145 9,498 153 107 3,128 3,232 31 37
Maine 18 36 570 547 16 - 39 31 - -
N.H. 22 19 513 431 22 25 49 60 - -
Vt. 10 24 224 214 8 6 19 27 - 2
Mass. 386 526 4,618 3,929 81 60 1,121 1,232 28 31
R.I. 67 83 1,347 1,086 5 1 195 256 3 4
Conn. 327 766 3,873 3,291 21 15 1,705 1,626 - -
MID. ATLANTIC 6,951 9,910 34,006 30,194 112 27 19,160 19,467 223 184
Upstate N.Y. 849 1,621 N N 79 - 3,245 3,358 171 135
N.Y. City 3,910 4,966 18,216 14,579 4 6 7,952 7,280 - -
N.J. 1,232 2,090 5,351 5,364 29 20 3,025 3,980 - -
Pa. 960 1,233 10,439 10,251 N 1 4,938 4,849 52 49
E.N. CENTRAL 1,768 2,281 47,677 40,616 198 111 32,548 24,505 291 346
Ohio 331 465 13,605 12,234 49 20 8,344 7,776 7 10
Ind. 326 360 3,265 4,761 55 25 2,078 3,186 3 10
Ill. 706 761 13,507 7,270 46 - 10,871 3,593 16 58
Mich. 305 544 12,004 10,372 48 27 9,110 7,484 265 248
Wis. 100 151 5,296 5,979 N 39 2,145 2,466 - 20
W.N. CENTRAL 444 615 17,185 17,428 161 95 8,609 7,872 120 39
Minn. 65 99 3,235 3,620 55 47 1,126 1,270 7 3
Iowa 49 69 2,063 2,575 51 7 660 690 12 19
Mo. 209 296 6,580 6,473 15 21 4,986 4,291 96 5
N. Dak. 4 6 290 470 2 6 29 32 - 2
S. Dak. 9 3 902 683 8 10 145 76 - -
Nebr. 39 59 1,273 1,100 19 - 450 419 2 2
Kans. 69 83 2,842 2,507 11 4 1,213 1,094 3 8
S. ATLANTIC 5,900 8,188 60,970 51,976 93 61 49,020 50,572 109 129
Del. 75 145 1,404 - - 1 762 639 - -
Md. 718 1,071 4,713 3,917 14 4 5,431 6,435 5 3
D.C. 481 613 N N 2 - 1,911 2,378 - -
Va. 425 654 6,476 6,520 N 25 3,604 4,496 7 18
W. Va. 57 62 1,485 1,605 5 3 432 504 4 11
N.C. 390 429 12,003 9,350 15 20 10,095 9,035 14 33
S.C. 386 422 10,270 6,935 4 1 6,642 6,223 3 27
Ga. 616 972 13,486 9,647 33 - 11,212 11,019 9 -
Fla. 2,752 3,820 11,133 14,002 20 7 8,931 9,843 67 37
E.S. CENTRAL 936 1,074 19,940 18,787 59 25 18,930 18,743 93 203
Ky. 127 177 3,438 3,636 16 - 1,959 2,320 16 9
Tenn. 333 469 7,198 7,006 27 22 6,160 5,811 74 134
Ala. 274 239 5,644 4,548 16 2 7,123 6,412 3 6
Miss. 202 189 3,660 3,597 U 1 3,688 4,200 U 54
W.S. CENTRAL 2,899 3,546 42,636 30,152 72 8 24,282 20,242 534 247
Ark. 104 130 1,939 1,598 6 3 1,190 2,652 3 9
La. 512 610 7,863 4,904 3 2 6,485 4,581 17 118
Okla. 170 165 5,459 4,077 10 3 3,011 2,560 7 5
Tex. 2,113 2,641 27,375 19,573 53 - 13,596 10,449 507 115
MOUNTAIN 831 935 11,698 15,576 153 61 4,369 4,237 244 170
Mont. 15 26 696 580 8 - 26 25 5 12
Idaho 15 28 946 818 14 7 91 61 86 30
Wyo. 2 13 357 315 47 - 17 29 45 41
Colo. 147 224 3 3,454 31 20 1,270 1,194 15 18
N. Mex. 130 80 2,083 2,089 13 6 500 478 56 32
Ariz. 329 227 6,081 5,731 13 12 2,201 1,819 3 22
Utah 65 80 1,223 942 20 10 126 137 21 3
Nev. 128 257 309 1,647 7 6 138 494 13 12
PACIFIC 3,370 4,518 46,483 38,291 155 97 9,510 8,885 504 553
Wash. 236 377 6,167 5,023 28 22 1,056 1,069 11 17
Oreg. 93 162 3,136 2,702 38 34 440 421 2 2
Calif. 2,962 3,914 35,123 28,832 87 35 7,643 6,908 436 440
Alaska 12 28 1,039 797 2 - 168 219 1 -
Hawaii 67 37 1,018 937 N 6 203 268 54 94
Guam - 2 8 193 N - 2 27 - -
P.R. 1,001 1,019 U U - U 228 353 - -
V.I. 17 57 N N N U U U U U
Amer. Samoa - - U U N U U U U U
C.N.M.I. - 1 N N N U 14 17 - 2
N: Not notifiable U: Unavailable -: no reported cases C.N.M.I.: Commonwealth of Northern Mariana Islands
*Updated monthly to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention,
last update June 28, 1998.
†National Electronic Telecommunications System for Surveillance.
§Public Health Laboratory Information System. 
Reporting Area
AIDS Chlamydia
Escherichia
coli  O157:H7
Gonorrhea
Hepatitis
C/NA,NBNETSS† PHLIS§
Cum.
1998*
Cum.
1997
Cum.
1998
Cum.
1997
Cum.
1998
Cum.
1998
Cum.
1998
Cum.
1997
Cum.
1998
Cum.
1997
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TABLE II. (Cont’d.) Provisional cases of selected notifiable diseases, United States,
weeks ending July 25, 1998, and July 19, 1997 (29th Week)
UNITED STATES 611 471 4,563 3,318 638 885 3,909 4,669 7,016 8,836 3,861
NEW ENGLAND 35 33 1,675 734 41 44 40 95 232 244 730
Maine 1 1 6 7 4 1 1 - 4 16 120
N.H. 3 4 26 7 3 2 1 - 6 9 35
Vt. 3 4 6 3 - 2 4 - 1 3 31
Mass. 12 10 307 172 14 21 24 45 123 134 238
R.I. 8 5 165 53 2 4 - 2 31 17 42
Conn. 8 9 1,165 492 18 14 10 48 67 65 264
MID. ATLANTIC 135 82 2,324 2,022 149 270 139 228 1,293 1,684 887
Upstate N.Y. 39 21 1,402 744 43 39 18 24 166 220 616
N.Y. City 19 7 10 106 68 171 29 48 810 867 U
N.J. 7 14 412 562 22 45 49 97 317 335 109
Pa. 70 40 500 610 16 15 43 59 U 262 162
E.N. CENTRAL 194 164 48 48 55 87 515 406 544 985 74
Ohio 82 71 40 15 3 11 76 120 U 169 40
Ind. 36 28 7 11 6 8 112 89 76 82 4
Ill. 14 7 - 7 18 37 188 51 296 509 5
Mich. 41 37 1 15 27 20 104 72 172 164 19
Wis. 21 21 U U 1 11 35 74 U 61 6
W.N. CENTRAL 41 32 42 42 48 28 82 98 203 296 444
Minn. 3 1 23 20 24 10 5 14 74 77 78
Iowa 4 8 13 2 5 6 - 4 U 34 97
Mo. 14 4 1 15 10 6 64 56 86 115 19
N. Dak. - 2 - - 2 2 - - 3 6 89
S. Dak. 2 2 - - - - 1 - 14 7 90
Nebr. 15 12 3 2 1 1 4 1 8 12 3
Kans. 3 3 2 3 6 3 8 23 18 45 68
S. ATLANTIC 74 63 338 318 146 138 1,720 1,860 1,089 1,772 1,171
Del. 8 7 8 73 1 2 15 15 U 18 17
Md. 17 13 237 198 45 44 394 515 162 165 291
D.C. 5 3 4 7 12 10 43 71 62 57 -
Va. 8 13 31 11 26 38 92 148 144 165 357
W. Va. N N 6 1 - - 2 3 24 29 49
N.C. 6 8 20 15 12 8 425 404 216 219 136
S.C. 5 3 3 1 4 9 170 222 181 194 92
Ga. 2 - 2 1 15 15 455 308 230 323 106
Fla. 23 16 27 11 31 12 124 174 70 602 123
E.S. CENTRAL 30 31 43 46 16 19 606 1,014 362 700 138
Ky. 15 7 10 8 2 5 67 85 - 103 21
Tenn. 11 17 22 20 10 4 315 430 200 258 85
Ala. 4 2 11 4 4 7 145 258 162 221 32
Miss. U 5 U 14 U 3 79 241 U 118 U
W.S. CENTRAL 20 8 10 36 18 10 511 681 64 1,402 109
Ark. - 1 5 11 1 2 67 106 64 118 21
La. 2 2 - 2 4 5 191 212 U 102 -
Okla. 8 1 - 5 2 3 32 67 U 122 88
Tex. 10 4 5 18 11 - 221 296 U 1,060 -
MOUNTAIN 35 29 7 6 29 45 123 91 231 321 94
Mont. 1 1 - - - 2 - - 12 6 32
Idaho - 2 1 2 3 - - - 8 8 -
Wyo. 1 1 - 1 - 2 1 - 2 2 43
Colo. 7 9 3 - 9 23 8 5 U 56 1
N. Mex. 2 1 2 - 11 6 12 4 33 27 3
Ariz. 7 7 - 1 5 5 97 72 114 145 9
Utah 16 5 - - 1 3 3 3 33 13 6
Nev. 1 3 1 2 - 4 2 7 29 64 -
PACIFIC 47 29 76 66 136 244 173 196 2,998 1,432 214
Wash. 7 6 2 2 9 9 12 7 144 169 -
Oreg. - - 8 10 11 13 3 5 66 94 1
Calif. 39 22 65 54 114 214 158 182 2,672 1,014 193
Alaska - - 1 - 1 3 - 1 27 47 20
Hawaii 1 1 - - 1 5 - 1 89 108 -
Guam - - - - - - - 3 - 13 -
P.R. - - - - - 3 118 134 46 129 30
V.I. U U U U U U U U U U U
Amer. Samoa U U U U U U U U U U U
C.N.M.I. - - - - - - 98 9 54 2 -
N: Not notifiable U: Unavailable -: no reported cases
*Additional information about areas displaying “U” for cumulative 1998 Tuberculosis cases can be found in Notice to Readers, MMWR
Vol. 47, No. 2, p. 39.
Reporting Area
Legionellosis
Lyme
Disease Malaria
Syphilis
(Primary & Secondary) Tuberculosis
Rabies,
Animal
Cum.
1998
Cum.
1997
Cum.
1998
Cum.
1997
Cum.
1998
Cum.
1997
Cum.
1998
Cum.
1997
Cum.
 1998*
Cum.
1997
Cum.
1998
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TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination,
United States, weeks ending July 25, 1998, 
and July 19, 1997 (29th Week)
UNITED STATES 624 666 12,053 15,445 4,496 5,149 - 26 - 14 40 90
NEW ENGLAND 34 36 150 395 74 95 - 1 - 2 3 13
Maine 2 3 13 45 2 6 - - - - - -
N.H. 6 5 8 21 10 6 - - - - - 1
Vt. 2 3 13 7 1 5 - - - 1 1 -
Mass. 22 22 46 167 18 40 - 1 - 1 2 11
R.I. 2 2 10 80 43 9 - - - - - -
Conn. - 1 60 75 - 29 - - - - - 1
MID. ATLANTIC 88 93 767 1,244 640 748 - 9 - 2 11 21
Upstate N.Y. 35 25 188 175 176 149 - 2 - - 2 5
N.Y. City 16 24 204 562 172 283 - - - - - 7
N.J. 32 30 160 187 105 148 - 7 - 1 8 3
Pa. 5 14 215 320 187 168 - - - 1 1 6
E.N. CENTRAL 95 110 1,577 1,616 463 862 - 11 - 3 14 8
Ohio 35 60 194 207 43 48 - - - 1 1 -
Ind. 27 11 95 178 59 69 - 2 - 1 3 -
Ill. 29 25 261 414 89 166 - - - - - 6
Mich. - 14 914 696 250 250 - 9 - 1 10 2
Wis. 4 - 113 121 22 329 - - - - - -
W.N. CENTRAL 60 34 958 1,161 243 281 - - - - - 11
Minn. 46 25 78 104 21 23 - - - - - 2
Iowa 1 3 382 193 37 21 - - - - - -
Mo. 8 3 391 618 151 206 - - - - - 1
N. Dak. - - 3 10 4 3 - - - - - -
S. Dak. - 2 17 14 1 - - - - - - 8
Nebr. - 1 23 49 9 8 - - - - - -
Kans. 5 - 64 173 20 20 - - - - - -
S. ATLANTIC 132 105 1,016 864 640 625 - 2 - 5 7 8
Del. - - 2 16 - 4 - - - 1 1 -
Md. 41 44 187 124 94 94 - - - 1 1 2
D.C. - - 30 15 6 24 - - - - - 1
Va. 13 7 137 114 56 74 - - - 2 2 1
W. Va. 4 3 1 6 3 9 - - - - - -
N.C. 18 17 59 113 119 134 - - - - - 1
S.C. 4 3 18 69 21 62 - - - - - -
Ga. 26 22 268 195 96 64 - - - 1 1 1
Fla. 26 9 314 212 245 160 - 2 - - 2 2
E.S. CENTRAL 36 38 206 372 220 380 - - - - - 1
Ky. 4 5 13 46 24 25 - - - - - -
Tenn. 24 23 144 229 163 255 - - - - - -
Ala. 8 8 49 58 33 41 - - - - - 1
Miss. U 2 U 39 U 59 U U U U U -
W.S. CENTRAL 36 32 2,294 3,126 746 649 - - - - - 5
Ark. - 2 58 134 52 47 - - - - - -
La. 16 7 46 117 57 82 - - - - - -
Okla. 18 21 332 924 48 22 - - - - - -
Tex. 2 2 1,858 1,951 589 498 - - - - - 5
MOUNTAIN 69 63 1,876 2,352 490 483 - - - - - 7
Mont. - - 63 53 3 5 - - - - - -
Idaho - 1 158 82 19 15 - - - - - -
Wyo. 1 2 24 20 2 14 - - - - - -
Colo. 15 10 148 252 62 91 - - - - - -
N. Mex. 5 7 88 183 211 159 - - - - - -
Ariz. 38 26 1,199 1,154 126 111 - - - - - 5
Utah 4 3 127 365 42 56 - - - - - -
Nev. 6 14 69 243 25 32 U - U - - 2
PACIFIC 74 155 3,209 4,315 980 1,026 - 3 - 2 5 16
Wash. 6 2 634 302 69 45 - - - 1 1 -
Oreg. 30 24 223 224 66 63 - - - - - -
Calif. 30 121 2,315 3,682 834 899 - 3 - 1 4 12
Alaska 1 2 14 24 6 11 - - - - - -
Hawaii 7 6 23 83 5 8 - - - - - 4
Guam - - - - - 3 U - U - - -
P.R. 2 - 28 191 257 435 - - - - - -
V.I. U U U U U U U U U U U U
Amer. Samoa U U U U U U U U U U U U
C.N.M.I. - 6 1 1 28 34 U - U - - 1
N: Not notifiable U: Unavailable -: no reported cases
*Of 146 cases among children aged <5 years, serotype was reported for 79 and of those, 33 were type b.
†For imported measles, cases include only those resulting from importation from other countries.
Reporting Area
H. influenzae,
invasive
Hepatitis (Viral), by type Measles (Rubeola)
A B Indigenous Imported† Total
Cum.
1998*
Cum.
1997
Cum.
1998
Cum.
1997
Cum.
1998
Cum.
1997 1998
Cum.
1998 1998
Cum.
1998
Cum.
1998
Cum.
1997
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UNITED STATES 1,653 2,145 5 266 376 71 2,519 2,946 2 287 121
NEW ENGLAND 75 134 - 1 7 17 456 592 - 36 1
Maine 5 15 - - - - 5 6 - - -
N.H. 4 12 - - - - 39 69 - - -
Vt. 1 2 - - - 2 44 180 - - -
Mass. 37 70 - 1 2 11 338 314 - 6 1
R.I. 3 9 - - 4 - 5 12 - 1 -
Conn. 25 26 - - 1 4 25 11 - 29 -
MID. ATLANTIC 152 225 - 16 43 4 298 225 2 121 29
Upstate N.Y. 38 62 - 3 9 3 149 83 - 107 5
N.Y. City 18 40 - 4 3 1 9 53 2 9 24
N.J. 41 43 - 1 7 - 5 11 - 4 -
Pa. 55 80 - 8 24 - 135 78 - 1 -
E.N. CENTRAL 251 318 3 46 47 4 216 284 - - 5
Ohio 92 116 1 20 18 3 79 85 - - -
Ind. 46 35 - 5 4 - 68 33 - - -
Ill. 60 91 1 3 8 - 16 35 - - 1
Mich. 29 47 1 18 14 1 36 31 - - -
Wis. 24 29 - - 3 - 17 100 - - 4
W.N. CENTRAL 140 162 - 20 12 17 210 172 - 27 -
Minn. 25 29 - 10 5 15 130 108 - - -
Iowa 23 37 - 6 6 - 40 9 - - -
Mo. 53 70 - 3 - - 16 31 - 2 -
N. Dak. 2 1 - 1 - - - 1 - - -
S. Dak. 6 4 - - - 1 6 3 - - -
Nebr. 7 6 - - 1 1 8 4 - - -
Kans. 24 15 - - - - 10 16 - 25 -
S. ATLANTIC 292 362 - 37 45 6 147 262 - 8 56
Del. 1 5 - - - - 2 - - - -
Md. 23 35 - - 1 - 29 82 - - -
D.C. - 5 - - - - 1 3 - - -
Va. 24 35 - 5 7 - 7 32 - - 1
W. Va. 9 14 - - - - 1 5 - - -
N.C. 42 69 - 9 7 - 50 73 - 5 49
S.C. 41 40 - 4 10 1 17 11 - - 6
Ga. 64 72 - 1 6 - 6 8 - - -
Fla. 88 87 - 18 14 5 34 48 - 3 -
E.S. CENTRAL 116 155 - 1 19 2 58 60 - - 1
Ky. 17 38 - - 3 - 22 16 - - -
Tenn. 45 54 - 1 3 1 19 23 - - -
Ala. 54 46 - - 6 1 17 15 - - 1
Miss. U 17 U U 7 U U 6 U U -
W.S. CENTRAL 190 200 - 40 44 - 181 110 - 77 3
Ark. 23 25 - - 1 - 26 8 - - -
La. 39 43 - 8 11 - 2 12 - - -
Okla. 29 23 - - - - 18 15 - - -
Tex. 99 109 - 32 32 - 135 75 - 77 3
MOUNTAIN 91 124 1 24 48 17 553 742 - 5 5
Mont. 3 7 - - - - 3 9 - - -
Idaho 4 8 - 3 2 - 194 455 - - 1
Wyo. 4 1 - 1 1 - 7 5 - - -
Colo. 19 33 1 6 3 9 120 194 - - -
N. Mex. 16 20 N N N 2 69 39 - 1 -
Ariz. 32 31 - 5 31 4 118 20 - 1 4
Utah 10 11 - 3 6 2 30 10 - 2 -
Nev. 3 13 U 6 5 U 12 10 U 1 -
PACIFIC 346 465 1 81 111 4 400 499 - 13 21
Wash. 47 55 - 6 13 - 153 210 - 9 5
Oreg. 55 92 N N N 2 29 22 - - -
Calif. 239 315 1 60 81 2 211 250 - 2 8
Alaska 1 1 - 2 5 - 2 4 - - -
Hawaii 4 2 - 13 12 - 5 13 - 2 8
Guam - 1 U - 1 U - - U - -
P.R. 6 8 - 1 5 - 2 - - - -
V.I. U U U U U U U U U U U
Amer. Samoa U U U U U U U U U U U
C.N.M.I. - - U 2 4 U 1 - U - -
N: Not notifiable U: Unavailable -: no reported cases
TABLE III. (Cont’d.) Provisional cases of selected notifiable diseases preventable
by vaccination, United States, weeks ending July 25, 1998, 
and July 19, 1997 (29th Week)
Reporting Area
Meningococcal
Disease Mumps Pertussis Rubella
Cum.
1998
Cum.
1997 1998
Cum.
1998
Cum.
1997 1998
Cum.
1998
Cum.
1997 1998
Cum.
1998
Cum.
1997
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NEW ENGLAND 543 379 98 42 13 11 32
Boston, Mass. 141 95 27 13 3 3 10
Bridgeport, Conn. 35 25 8 1 - 1 3
Cambridge, Mass. 15 10 4 1 - - 1
Fall River, Mass. 18 15 2 1 - - 2
Hartford, Conn. 55 34 10 9 1 1 -
Lowell, Mass. 25 18 3 3 1 - -
Lynn, Mass. 6 4 2 - - - 1
New Bedford, Mass. 14 10 2 1 1 - 1
New Haven, Conn. 31 16 8 4 2 1 1
Providence, R.I. 66 49 11 3 2 1 -
Somerville, Mass. 6 4 2 - - - -
Springfield, Mass. 33 18 11 1 2 1 -
Waterbury, Conn. 41 30 7 2 1 1 3
Worcester, Mass. 57 51 1 3 - 2 10
MID. ATLANTIC 2,211 1,483 449 189 51 39 88
Albany, N.Y. 58 33 17 4 2 2 4
Allentown, Pa. 18 11 5 - 2 - -
Buffalo, N.Y. 71 52 15 4 - - 7
Camden, N.J. 34 22 7 1 1 3 -
Elizabeth, N.J. 20 15 3 2 - - -
Erie, Pa. 41 31 5 4 - 1 3
Jersey City, N.J. 28 13 8 5 - 2 -
New York City, N.Y. 1,144 760 232 118 21 13 31
Newark, N.J. U U U U U U U
Paterson, N.J. 17 8 5 3 - 1 -
Philadelphia, Pa. 400 265 76 32 15 12 22
Pittsburgh, Pa.§ 58 38 16 3 - 1 3
Reading, Pa. 38 33 3 2 - - 1
Rochester, N.Y. 112 82 19 8 2 1 3
Schenectady, N.Y. 26 17 7 - 1 1 2
Scranton, Pa. 22 12 5 1 4 - -
Syracuse, N.Y. 77 61 14 - 1 1 9
Trenton, N.J. 28 15 9 2 1 1 2
Utica, N.Y. 19 15 3 - 1 - 1
Yonkers, N.Y. U U U U U U U
E.N. CENTRAL 1,549 1,101 250 92 66 40 79
Akron, Ohio 34 27 4 1 1 1 1
Canton, Ohio 37 29 6 2 - - 4
Chicago, Ill. U U U U U U U
Cincinnati, Ohio 96 62 14 6 7 7 5
Cleveland, Ohio 133 91 24 8 5 5 5
Columbus, Ohio 190 130 38 15 4 3 12
Dayton, Ohio 106 77 15 6 3 5 6
Detroit, Mich. 180 108 39 18 11 4 3
Evansville, Ind. 39 32 3 1 3 - 1
Fort Wayne, Ind. 60 45 11 2 2 - 5
Gary, Ind. 13 4 4 1 3 1 -
Grand Rapids, Mich. 52 43 4 1 1 3 4
Indianapolis, Ind. 174 126 24 12 8 4 5
Lansing, Mich. 35 27 7 - 1 - 8
Milwaukee, Wis. 104 79 19 3 2 1 5
Peoria, Ill. 51 40 6 - 4 1 2
Rockford, Ill. 39 30 3 3 2 1 3
South Bend, Ind. 48 39 4 3 2 - 4
Toledo, Ohio 103 70 19 8 5 1 4
Youngstown, Ohio 55 42 6 2 2 3 2
W.N. CENTRAL 764 523 144 48 25 19 36
Des Moines, Iowa 64 43 11 7 1 2 5
Duluth, Minn. 39 24 10 5 - - 2
Kansas City, Kans. 40 19 15 3 3 - 1
Kansas City, Mo. 68 43 10 6 3 1 1
Lincoln, Nebr. 33 28 4 - 1 - 2
Minneapolis, Minn. 191 135 37 13 3 3 8
Omaha, Nebr. 72 51 13 2 3 3 7
St. Louis, Mo. 112 70 21 5 8 8 5
St. Paul, Minn. 55 47 7 1 - - 2
Wichita, Kans. 90 63 16 6 3 2 3
S. ATLANTIC 951 626 196 84 24 21 49
Atlanta, Ga. U U U U U U U
Baltimore, Md. 126 68 37 13 5 3 10
Charlotte, N.C. 85 61 13 6 1 4 10
Jacksonville, Fla. 140 102 24 11 1 2 5
Miami, Fla. 100 70 19 9 1 1 -
Norfolk, Va. 41 34 3 2 1 1 1
Richmond, Va. 66 40 13 8 4 1 2
Savannah, Ga. 40 27 10 1 1 1 4
St. Petersburg, Fla. 47 34 8 3 2 - 2
Tampa, Fla. 164 114 29 16 4 1 12
Washington, D.C. 129 69 35 14 4 7 3
Wilmington, Del. 13 7 5 1 - - -
E.S. CENTRAL 607 415 112 42 23 14 28
Birmingham, Ala. U U U U U U U
Chattanooga, Tenn. 89 61 17 3 8 - 5
Knoxville, Tenn. 92 69 17 4 - 2 10
Lexington, Ky. 71 46 13 6 4 2 2
Memphis, Tenn. 122 81 27 6 3 5 9
Mobile, Ala. 67 44 13 4 4 2 -
Montgomery, Ala. 43 34 2 6 - 1 1
Nashville, Tenn. 123 80 23 13 4 2 1
W.S. CENTRAL 1,438 926 281 134 45 52 91
Austin, Tex. 80 54 14 10 2 - 4
Baton Rouge, La. 21 15 3 2 - 1 -
Corpus Christi, Tex. 52 39 7 3 3 - 4
Dallas, Tex. 209 123 47 20 5 14 5
El Paso, Tex. 60 43 9 4 2 2 3
Ft. Worth, Tex. 106 75 14 6 8 3 9
Houston, Tex. 351 200 81 47 10 13 25
Little Rock, Ark. 71 43 19 2 3 4 4
New Orleans, La. 91 58 21 8 2 2 -
San Antonio, Tex. 187 132 31 16 5 3 15
Shreveport, La. 97 67 19 7 4 - 10
Tulsa, Okla. 113 77 16 9 1 10 12
MOUNTAIN 939 624 170 94 33 18 55
Albuquerque, N.M. 73 43 15 10 5 - 1
Boise, Idaho 43 35 5 1 - 2 6
Colo. Springs, Colo. 43 24 8 7 2 2 1
Denver, Colo. 113 67 26 14 2 4 6
Las Vegas, Nev. 225 156 39 16 11 3 10
Ogden, Utah 22 14 3 2 3 - 2
Phoenix, Ariz. 173 119 23 19 6 6 14
Pueblo, Colo. 38 30 6 2 - - 2
Salt Lake City, Utah 111 75 19 14 2 1 8
Tucson, Ariz. 98 61 26 9 2 - 5
PACIFIC 1,875 1,338 331 132 29 45 143
Berkeley, Calif. 18 14 2 - - 2 1
Fresno, Calif. 127 91 21 13 2 - 7
Glendale, Calif. 52 39 11 2 - - 3
Honolulu, Hawaii 83 58 19 2 2 2 6
Long Beach, Calif. 68 51 12 2 - 3 11
Los Angeles, Calif. 594 444 100 37 5 8 35
Pasadena, Calif. 20 12 3 1 - 4 2
Portland, Oreg. U U U U U U U
Sacramento, Calif. 195 137 28 22 3 5 24
San Diego, Calif. 113 68 28 9 6 2 9
San Francisco, Calif. 118 78 21 11 1 7 9
San Jose, Calif. 184 131 37 10 2 4 21
Santa Cruz, Calif. 34 27 4 3 - - 8
Seattle, Wash. 144 95 25 14 7 3 3
Spokane, Wash. 54 42 8 2 - 2 2
Tacoma, Wash. 71 51 12 4 1 3 2
TOTAL 10,877
¶
7,415 2,031 857 309 259 601
Reporting Area
>65 45-64 25-44 1-24 <1
P&I
†
TotalAll
Ages
All  Causes, By Age (Years)
Reporting Area
P&I
†
TotalAll
Ages
All  Causes, By Age (Years)
>65 45-64 25-44 1-24 <1
U: Unavailable    -: no reported cases
*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or
more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not
included.
†Pneumonia and influenza.
§Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete
counts will be available in 4 to 6 weeks.
¶Total includes unknown ages.
TABLE IV. Deaths in 122 U.S. cities,* week ending
July 25, 1998 (29th Week)
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Quarterly Immunization Table
To track progress toward achieving the goals of the Childhood Immunization Initia-
tive (CII), CDC publishes quarterly a tabular summary of the number of cases of na-
tionally notifiable diseases preventable by routine childhood vaccination reported
during the previous quarter and the year to date (provisional data). In addition, the
table compares provisional data with provisional data for the previous year and high-
lights the number of reported cases among children aged <5 years, who are the pri-
mary focus of CII. Data in the table are reported through the National Electronic
Telecommunications System for Surveillance.
Number of reported cases of nationally notifiable diseases preventable by routine
childhood vaccination — United States, April–June 1998 and January–June 1997 and
1998*
Disease
  No. cases,
  April–June
  1998
  Total cases  
January–June 
 No. cases among
children aged <5 years†
January–June
  1997   1998   1997   1998 
Congenital rubella
syndrome 2 3 3 3 3
Diphtheria 1 4 1 1 0
Haemophilus influenzae§ 275 588 544 113 132
Hepatitis B¶ 2122 4430 3809 39 37
Measles 28 77 37 28 17
Mumps 129 339 236 64 41
Pertussis 1130 2537 2075 1021 818
Poliomyelitis, paralytic** 0 2 1 1 1
Rubella 147 64 251 7 13
Tetanus 10 22 12 0 1
 *Data for 1997 and 1998 are provisional.
†For 1997 and 1998, age data were available for ≥96% of cases.
§Invasive disease; H. influenzae  serotype is not routinely reported to the National Notifiable
Diseases Surveillance System. Of 132 cases among children aged <5 years, serotype was
reported for 74 cases, and of those, 32 were type b, the only serotype of H. influenzae
preventable by vaccination.
¶Because most hepatitis B virus infections among infants and children aged <5 years are
asymptomatic (although likely to become chronic), acute disease surveillance does not
reflect the incidence of this problem in this age group or the effectiveness of hepatitis B vac-
cination in infants.
**One case with onset in 1998 and three cases with onset in 1997 have been confirmed. All
were associated with administration of oral poliovirus vaccine. One suspected case with
onset in 1997 remains under investigation.
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